sur Pentixapharm Holding AG (isin : DE000A40AEG0)
Pentixapharm Secures EUR 6.77 Million from Glycotope Assets
Berlin-based Pentixapharm AG has announced a significant financial gain, receiving EUR 6.77 million for intangible assets formerly associated with Glycotope. These assets were acquired as part of Pentixapharm’s purchase of Glycotope’s target discovery business in July 2024. The transaction involved undisclosed Asian pharmaceutical and biotech companies and is expected to be finalized within 2024.
This deal reduces Pentixapharm’s obligations from the earn-out agreements linked to the acquisition. Although it doesn't markedly impact Pentixapharm's financial losses for 2024, it underlines the pharmaceutical sector's confidence in the company's strategic assets. Pentixapharm's acquisition includes preclinical antibodies, a tumor target database, and essential IP for further scientific exploration.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Pentixapharm Holding AG